Another study showed in non-small cell lung cancer patients that a positive phospho-Erk activity might be correlated with a poor response to Gefitinib while high phospho-Akt combined with a negative phospho-Erk, or EGFR mutations associated with expression of HER2/3 could predict efficiency of this drug [38, 39]. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.